Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Cell Research Corporation (CRC) Announces Positive Results of Phase I Study for CorLiCyte®
Details : CorLiCyte® is a live mesenchymal stem cell therapy derived from human umbilical cord lining stem cells, with a proprietary optimised expression of cytokines, growth and cellular factors for the treatment of a number of serious health conditions.
Brand Name : CorLiCyte
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
September 16, 2022
LOOKING FOR A SUPPLIER?